Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Fred Hutchinson Cancer Research Center, Seattle, Washington.
Cancer Res. 2014 Sep 1;74(17):4694-705. doi: 10.1158/0008-5472.CAN-13-3725. Epub 2014 Jun 26.
Cancer/testis (CT) antigens are potential immunotherapeutic targets in cancer. However, the expression of particular antigens is limited to a subset of tumors of a given type. Thus, there is a need to identify antigens with complementary expression patterns for effective therapeutic intervention. In this study, we searched for genes that were distinctly expressed at a higher level in lung tumor tissue and the testes compared with other nontumor tissues and identified members of the VCX/Y gene family as novel CT antigens. VCX3A, a member of the VCX/Y gene family, was expressed at the protein level in approximately 20% of lung adenocarcinomas and 35% of squamous cell carcinomas, but not expressed in normal lung tissues. Among CT antigens with concordant mRNA and protein expression levels, four CT antigens, XAGE1, VCX, IL13RA2, and SYCE1, were expressed, alone or in combination, in about 80% of lung adenocarcinoma tumors. The CT antigen VCX/Y gene family broadens the spectrum of CT antigens expressed in lung adenocarcinomas for clinical applications.
癌症/睾丸（CT）抗原是癌症免疫治疗的潜在靶点。然而，特定抗原的表达仅限于特定类型肿瘤的一部分。因此，需要确定具有互补表达模式的抗原，以进行有效的治疗干预。在这项研究中，我们搜索了在肺癌组织和睾丸中表达水平明显高于其他非肿瘤组织的基因，并将 VCX/Y 基因家族的成员鉴定为新的 CT 抗原。VCX3A 是 VCX/Y 基因家族的成员，在大约 20%的肺腺癌和 35%的鳞状细胞癌中表达蛋白水平，但在正常肺组织中不表达。在具有一致 mRNA 和蛋白表达水平的 CT 抗原中，四个 CT 抗原，XAGE1、VCX、IL13RA2 和 SYCE1，单独或组合表达在大约 80%的肺腺癌肿瘤中。CT 抗原 VCX/Y 基因家族拓宽了肺腺癌中表达的 CT 抗原谱，可用于临床应用。
